Coronavirus disease 2019 (COVID-19) and immune-mediated rheumatic diseases. Recommendations of the association of rheumatologists of Russia
E. L. Nasonov,A. M. Lila,Vadim I. Mazurov,B. S. Belov,A. E. Karateev,Tatiana Dubinina,O. A. Nikitinskaya,A. A. Baranov,Diana Abdulganieva,S. V. Moiseev,A. I. Zagrebneva +10 more
- Vol. 59, Iss: 3, pp 239-254
Reads0
Chats0
TLDR
The new version of the recommendations of the Association of Rheumatologists of Russia formulates the main provisions concerning the tactics of managing patients with Immune-mediated Rheumatic Diseases during the ongoing COVID-19 pandemic.Citations
More filters
Journal ArticleDOI
Деплеция в-клеток при иммуновоспалительных ревматических заболеваниях и коронавирусная болезнь 2019 (covid-19)
Е. Л. Насонов,А. С. Авдеева +1 more
TL;DR: According to the recommendations of the Association of Rheumatologists of Russia, a more rigorous assessment of indications for induction and maintenance therapy of RTX therapy and harmonization of the timing of drug administration and vaccination is required.
Journal ArticleDOI
Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues
TL;DR: The frequency of exacerbation of RD after vaccination against COVID-19 seems to be quite low (5–7%) and has no significant associations with a specific vaccine or anti-rheumatic therapy, and unambiguous interpretation is difficult.
Journal ArticleDOI
Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology
Evgeny Nasonov,T.V. Korotaeva +1 more
TL;DR: The current achievements, trends and recommendations regarding the use of JAK inhibitors in the treatment of IMIDs and also in the hyper-response phase of COVID-19 are reviewed.
Journal ArticleDOI
Rheumatoid arthritis and post-COVID-19 syndrome
TL;DR: It is thought that SARS-CoV-2 infection may be a trigger factor for new rheumatic musculoskeletal diseases, including rheumatoid arthritis or COVID-19 can unmask previously undetected RA, and arthritis in the post covid period may induce problems in differential diagnosis of rhematic diseases.
Journal ArticleDOI
Safety of COVID-19 vaccines in patients with immunoinflammatory rheumatic diseases (preliminary data)
TL;DR: Preliminary data suggest that vaccination against COVID-19 in patients with IRD appears to be quite safe, and further studies are needed to investigate the safety, immunogenicity, and clinical efficacy of CO VID-19 immunization in rheumatic patients.
References
More filters
Journal ArticleDOI
Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020.
Olivier Lortholary,Mario Fernández-Ruiz,John W Baddley,Oriol Manuel,Xavier Mariette,Kevin L. Winthrop +5 more
TL;DR: A multidisciplinary group of experts deeply involved in the use of targeted and biological therapies in rheumatoid and psoriatic arthritis decided to summarise their recent vision of the immunological basis and epidemiology of infections occurring during targeted and Biological therapies, and provide useful indications for their management and prevention.
Journal ArticleDOI
Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD.
Maurizio Benucci,Arianna Damiani,Gianfranco Giannasi,Francesca Li Gobbi,Luca Quartuccio,Valentina Grossi,Maria Infantino,Mariangela Manfredi +7 more
TL;DR: Data analysis showed a slightly increased risk of hospitalisation for prednisone doses of ≥10 mg, while biological disease-modifying anti-rheumatic drug (b-DMARD) monotherapy just prior to COVID-19 diagnosis appeared protective, in particular, the tumour necrosis factor targeting agents, as result of a subsequent subanalysis.
Posted ContentDOI
Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
Xabier Michelena,Xabier Michelena,Helena Borrell,Mireia López-Corbeto,María López-Lasanta,Estefanía Moreno,María Pascual-Pastor,Alba Erra,Mayte Serrat,Esther Espartal,Susana Antón,Gustavo Adolfo Añez,Raquel Caparrós-Ruiz,Andrea Pluma,Ernesto Trallero-Araguás,Mireia Barceló-Bru,Miriam Almirall,Juan José De Agustín,Jordi Lladós Segura,Antonio Julià,Sara Marsal +20 more
TL;DR: Adult and paediatric patients with rheumatic diseases on tDMARDs do not seem to present a higher risk of COVID-19 or a more severe disease outcome when compared to general population.
Journal ArticleDOI
Systematic review of immunosuppressant guidelines in the COVID-19 pandemic
TL;DR: In this article, a lack of evidence about the effectiveness of immunosuppressants in the detection of COVID-19 was found, due to the novel nature of the COVID19.
Journal ArticleDOI
Recommendations for the management of patients with systemic rheumatic diseases during the coronavirus disease pandemic
Mi Ryoung Seo,Ji-Won Kim,Eun Jung Park,Seung Min Jung,Yoon-Kyoung Sung,Hyung-Jin Kim,Gunwoo Kim,Hyun-Sook Kim,Myeung-Su Lee,Jisoo Lee,Ji An Hur,Bum Sik Chin,Joong Sik Eom,Han Joo Baek +13 more
TL;DR: The Korean College of Rheumatology recognized the urgent need to develop recommendations for rheumatologists and other physicians to manage patients with SRD during the COVID-19 pandemic and developed four general principles and thirteen individual recommendations based on the available evidence.